viralic
Forumer storico
Acqua......sei molto lontano !!!
NicOx.... in attesa di.....
- Creatore Discussione DickSIM
- Data di Inizio
Acqua......sei molto lontano !!!
viralic
Forumer storico
Hai risposto che aspetti di recuperare i tuoi soldi.....a 8 euro....ma se non ci credi vendi....altrimenti se pensi che torni a 8 euro compra e media il prezzo cos' potrai uscire a 7 in pareggio.
PIZZODIGINO
Pacifico
guly ti do un consiglio:consiglio: vai a passeggiare e riapri il sito di nicox in ottobre, troverai delle belle sorprese.
elcucador
Forumer storico
allora lo cedono ad una rete di vendita indipendente e sara' nicox a pagare le royalties sul venduto,tenendosi questa volta la fetta piu' grossa?
elcucador
Forumer storico
hai ragione ma purtroppo ogni tanto mi faccio prendere la mano e rientro sul forum in maniera eccessiva.
hai ragione stacco di nuovo e mi occupo di cose piu' piacevoli e rilassanti.
ripassero' ogni tanto.
viralic
Forumer storico
Acqua......ma anche se in minima parte qualcosa è corretto....ma per la parte più importante sei ancora lontano
PIZZODIGINO
Pacifico
dai Viralic non tenerci in sospeso, dicci quello che sai ((se puoi)
Stefano fib
Nuovo forumer
Volumi in forte crescita nelle prime battute... Chissà!!!
viralic
Forumer storico
ovvio.......aumento si scambi ridicolo comunque !!
NICOX signe un accord sur pour la Chine
AOF•15/03/2019 à 08:55
(AOF) - Nicox annonce la conclusion d'un accord de licence exclusif avec Ocumension Therapeutics pour le développement et la commercialisation de son produit, ZERVIATETM (solution ophtalmique de cetirizine), 0,24%, pour le traitement des conjonctivites allergiques sur un territoire comprenant la Chine continentale, Hong Kong, Macao et Taiwan. Nicox a concédé à Ocumension les droits exclusifs de développement et de commercialisation de ZERVIATE sur ce territoire précité.
Ainsi, le groupe pourrait potentiellement recevoir d'Ocumension des paiements d'étape liés au développement et aux ventes d'un montant pouvant atteindre jusqu'à 17 millions d'euros ainsi que des redevances échelonnées de 5% à 9% sur les ventes de ZERVIATE.
PIZZODIGINO
Pacifico
Nicox signs agreement for ZERVIATE in China for up to €17 million in milestone payments plus royalties
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, and Ocumension Therapeutics today announced they have entered into an exclusive license agreement for the development and commercialization of Nicox’s product ZERVIATETM (cetirizine ophthalmic solution), 0.24% for the treatment of allergic conjunctivitis for a territory comprising mainland China, Hong Kong, Macau and Taiwan. Nicox and Ocumension recently also entered into a collaboration for the development and commercialization of NCX 470 for patients with glaucoma or ocular hypertension, in the same territory. Ocumension Therapeutics is an ophthalmology company funded by 6 Dimensions Capital, one of the leading global healthcare investment funds, formed by the merger of Wuxi Healthcare Ventures and Frontline BioVentures.
Ocumension will receive exclusive rights for the agreed territory to develop and commercialize ZERVIATE. Under the terms of the agreement, Nicox may potentially receive development and sales milestones of up €17 million together with royalties of between 5% and 9% on sales of ZERVIATE.
“Following our collaboration on NCX 470, Ocumension was the obvious choice for us to partner with for ZERVIATE in this region.” said Gavin Spencer, Chief Business Officer of Nicox. “Nicox has built a track record of successful partnerships, and we are actively engaged in discussions to further maximize the value of our commercial and development assets outside of the U.S. and the EU markets. We look forward to announcing more international collaborations for ZERVIATE in the coming months.”
“ZERVIATE brings Ocumension an additional late stage opportunity and expands our therapeutic area coverage into ocular allergy,” said Ye Liu, Chief Executive Officer of Ocumension. “We very much appreciate the collaboration with the Nicox team, and this deal further strengthens our relationship with one of the leading R&D companies in the ophthalmology space.”
Ocumension is expected to have to conduct additional clinical studies for the regulatory approval of ZERVIATE in the Chinese market. All development activities will be overseen by a Joint Development Committee comprising representatives of both companies, with Ocumension responsible for undertaking all the activities at its own cost.
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, and Ocumension Therapeutics today announced they have entered into an exclusive license agreement for the development and commercialization of Nicox’s product ZERVIATETM (cetirizine ophthalmic solution), 0.24% for the treatment of allergic conjunctivitis for a territory comprising mainland China, Hong Kong, Macau and Taiwan. Nicox and Ocumension recently also entered into a collaboration for the development and commercialization of NCX 470 for patients with glaucoma or ocular hypertension, in the same territory. Ocumension Therapeutics is an ophthalmology company funded by 6 Dimensions Capital, one of the leading global healthcare investment funds, formed by the merger of Wuxi Healthcare Ventures and Frontline BioVentures.
Ocumension will receive exclusive rights for the agreed territory to develop and commercialize ZERVIATE. Under the terms of the agreement, Nicox may potentially receive development and sales milestones of up €17 million together with royalties of between 5% and 9% on sales of ZERVIATE.
“Following our collaboration on NCX 470, Ocumension was the obvious choice for us to partner with for ZERVIATE in this region.” said Gavin Spencer, Chief Business Officer of Nicox. “Nicox has built a track record of successful partnerships, and we are actively engaged in discussions to further maximize the value of our commercial and development assets outside of the U.S. and the EU markets. We look forward to announcing more international collaborations for ZERVIATE in the coming months.”
“ZERVIATE brings Ocumension an additional late stage opportunity and expands our therapeutic area coverage into ocular allergy,” said Ye Liu, Chief Executive Officer of Ocumension. “We very much appreciate the collaboration with the Nicox team, and this deal further strengthens our relationship with one of the leading R&D companies in the ophthalmology space.”
Ocumension is expected to have to conduct additional clinical studies for the regulatory approval of ZERVIATE in the Chinese market. All development activities will be overseen by a Joint Development Committee comprising representatives of both companies, with Ocumension responsible for undertaking all the activities at its own cost.
